$29.96
-1.48-4.71%
In chiusura: Nov 20, 4:00 PM EST
$29.96
N/A
Post-mercato: 4:00 PM EST

The average analyst price target for Viridian Therapeutics is $41.53, 38.6% above the current price. Of 19 analysts, 17 rate it Buy and 2 Hold. Targets range from $20 to $61. The latest change came on Nov 19, 2026, when B of A Securities initiated coverage of Viridian Therapeutics with a Buy rating and a $47 price target.
Price Target Range — 13 Quarters
Analyst Consensus — 19 Analysts
Rating Trend — Last 9 Months